Updated Jul 16, 2026
SAHA SAURABH has filed 1 SEC Form 4 filing across 1 company in the last 90 days — selling. Lifetime open-market sales: $5.93M.
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-05-15 | CLVT | CLARIVATE PLC | A — Grant or award | 62.3K | $0.00 | |
| 2026-05-15 | CLVT | CLARIVATE PLC | F — Tax withholding / forfeiture | 8.2K | $2.44 | $20K |
| 2025-07-21 | CNTA | Centessa Pharmaceuticals plc | S — Open-market sale | 55.0K | $15.92 | $876K |
| 2025-07-21 | CNTA | Centessa Pharmaceuticals plc | M — Option exercise | 55.0K | $3.85 | $212K |
| 2024-12-31 | CNTA | Centessa Pharmaceuticals plc | F — Tax withholding / forfeiture | 36.3K | $16.35 | $593K |
| 2024-12-20 | CNTA | Centessa Pharmaceuticals plc | S — Open-market sale [10b5-1] | 55.0K | $17.44 | $959K |
| 2024-12-06 | CNTA | Centessa Pharmaceuticals plc | S — Open-market sale [10b5-1] | 87.5K | $18.46 | $1.62M |
| 2024-12-06 | CNTA | Centessa Pharmaceuticals plc | M — Option exercise [10b5-1] | 87.5K | $5.84 | $511K |
| 2024-11-27 | CNTA | Centessa Pharmaceuticals plc | S — Open-market sale [10b5-1] | 299 | $18.23 | $5K |
| 2024-11-27 | CNTA | Centessa Pharmaceuticals plc | M — Option exercise [10b5-1] | 299 | $5.84 | $2K |
| 2024-11-22 | CNTA | Centessa Pharmaceuticals plc | S — Open-market sale [10b5-1] | 1.7K | $18.24 | $30K |
| 2024-11-22 | CNTA | Centessa Pharmaceuticals plc | M — Option exercise [10b5-1] | 1.7K | $5.84 | $10K |
| 2024-11-22 | CNTA | Centessa Pharmaceuticals plc | S — Open-market sale [10b5-1] | 3.5K | $18.24 | $64K |
| 2024-11-22 | CNTA | Centessa Pharmaceuticals plc | M — Option exercise [10b5-1] | 3.5K | $5.84 | $21K |
| 2024-11-22 | CNTA | Centessa Pharmaceuticals plc | S — Open-market sale [10b5-1] | 55.0K | $16.89 | $929K |
| 2024-11-15 | CNTA | Centessa Pharmaceuticals plc | S — Open-market sale [10b5-1] | 32.0K | $18.28 | $585K |
| 2024-11-15 | CNTA | Centessa Pharmaceuticals plc | M — Option exercise [10b5-1] | 32.0K | $5.84 | $187K |
| 2024-10-23 | CNTA | Centessa Pharmaceuticals plc | S — Open-market sale [10b5-1] | 2.6K | $15.32 | $40K |
| 2024-10-23 | CNTA | Centessa Pharmaceuticals plc | S — Open-market sale [10b5-1] | 30.2K | $15.67 | $473K |
| 2024-10-23 | CNTA | Centessa Pharmaceuticals plc | S — Open-market sale [10b5-1] | 22.2K | $15.80 | $351K |
SAHA SAURABH is a corporate insider — currently tracked as Director of CLARIVATE PLC (CLVT). InsiderAlpha tracks every SEC Form 4 filing in real time.
1 primary Form 4 filings in the last 90 days, covering 1 company.
Recorded transactions: 0 open-market purchases () and 11 open-market sales ($5.93M) across all tracked filings.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live SAHA SAURABH profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.